GENMAB AS DK 1 | 361.300 / -1.04% |
Date/Time | 01/20 / 21:16 |
Chg. / Chg.(%) | -3.800 / -1.04% |
Bid | 359.700 / 15 |
Ask | 362.700 / 15 |
Open | 367.100 |
Previous Close | 365.100 |
High | 367.100 |
Low | 359.500 |
Volume [EUR] | 129,763.000 |
Volume [Units] | 359 |
Price fixings | 19 |
ISIN | DK0010272202 |
Security | GE9 |
Exchange | TradeGate |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
OMX Nordic | 2,676.00 | ![]() |
155,729 |
Cboe Europe .. | 2,676.00 | ![]() |
24,243 |
Turquoise | 2,682.00 | ![]() |
12,845 |
London Inter.. | 2,684.0 | ![]() |
9,144 |
Nasdaq Other.. | 440.5000 | ![]() |
650 |
Cboe Europe .. | 2,679.00 | ![]() |
377 |
TradeGate | 361.300 | ![]() |
359 |
Cboe Europe .. | 2,684.00 | ![]() |
100 |
München | 361.00 | ![]() |
92 |
gettex | 358.600 | ![]() |
43 |
Frankfurt | 361.9000 | ![]() |
8 |
Vienna Globa.. | 360.30 | ![]() |
0 |
Düsseldorf | 357.10 | ![]() |
0 |
Berlin | 358.80 | ![]() |
0 |
Stuttgart | 360.200 | ![]() |
0 |
Lang & Schwa.. | 361.20 | ![]() |
|
Mexico | 7,292.62 | ![]() |
111 |
News
- Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
01/15/2021 / 20:17 - GlobeNewswire - Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
01/13/2021 / 15:20 - GlobeNewswire - Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
01/04/2021 / 20:00 - GlobeNewswire - Genmab Announces Enapotamab Vedotin Update
11/24/2020 / 16:40 - GlobeNewswire - Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
11/05/2020 / 14:38 - GlobeNewswire
Personal area
Click on
to activate push quotes.
